← Leaderboards

Sharon L Hillier

Magee-Women'S Hospital Of Upmc

Google Scholar ↗PubMed ↗ORCID ↗

$240,179,607

Attributed

$271,312,760

Total exposure

18

Grants

10

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $33.3M · FY2005–25

$50M$37.5M$25M$12.5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$327,003,506 · 24

By mechanism

UM1$174,987,238 · 1

U01$79,577,598 · 6

U19$55,182,646 · 11

P30$12,035,397 · 1

P01$3,567,921 · 2

R01$1,316,680 · 1

Top collaborators

Most similar at Magee-Women'S Hospital Of Upmc

Same institution · by research overlap

Lisa C Rohan$28,808,820

Others in their field

Top investigators on “Aids Prevention”

Judith S. Currier · University Of California Los Angeles$494,857,170
Joseph J. Eron · Univ Of North Carolina Chapel Hill$398,787,960
Glenda E Gray · Wits Health Consortium (Pty), Ltd$310,253,675
Lawrence Corey · Fred Hutchinson Cancer Center$298,388,501
Constance Ann Benson · University Of California, San Diego$291,928,206
Daniel R Kuritzkes · Brigham And Women'S Hospital$281,830,629

Research focus

Aids PreventionClinical ResearchWomanHiv InfectionsBaseMicrobicideResearch PersonnelProgramsLaboratoriesEvaluationUniversitiesClinical TrialsPharmaceutical PreparationsCollaborationsLinkInnovationLeadershipVaginaProtocols DocumentationUnited States National Institutes Of HealthGrantSafetySiteFemale

Grant awards (101)

Rustbelt Center for AIDS Research (Case/UHC-Pitt CFAR)$2,185,970

P30 · FY2025 · AI

Rustbelt Center for AIDS Research (Case/UHC-Pitt CFAR)$2,250,000

P30 · FY2024 · AI

Rustbelt Center for AIDS Research (Case/UHC-Pitt CFAR)$959,560

P30 · FY2024 · AI

Rustbelt Center for AIDS Research (Case/UHC-Pitt CFAR)$395,644

P30 · FY2024 · AI

Rustbelt Center for AIDS Research (Case/UHC-Pitt CFAR)$241,291

P30 · FY2024 · AI

Rustbelt Center for AIDS Research (Case/UHC-Pitt CFAR)$238,501

P30 · FY2024 · AI

Rustbelt Center for AIDS Research (Case/UHC-Pitt CFAR)$238,013

P30 · FY2024 · AI

Rustbelt Center for AIDS Research (Case/UHC-Pitt CFAR)$2,411,000

P30 · FY2023 · AI

Rustbelt Center for AIDS Research (Case/UHC-Pitt CFAR)$241,291

P30 · FY2023 · AI

Rustbelt Center for AIDS Research (Case/UHC-Pitt CFAR)$240,018

P30 · FY2023 · AI

Rustbelt Center for AIDS Research (Case/UHC-Pitt CFAR)$223,109

P30 · FY2023 · AI

Rustbelt Center for AIDS Research (Case/UHC-Pitt CFAR)$2,411,000

P30 · FY2022 · AI

Leadership and Operations Center (LOC): Microbicide Trials Network$3,164,556

UM1 · FY2021 · AI · contact PI

Leadership and Operations Center (LOC): Microbicide Trials Network$14,462,896

UM1 · FY2020 · AI · contact PI

Hormones, Immunity and HIV Risk$434,251

R01 · FY2020 · HD · contact PI

Leadership and Operations Center (LOC): Microbicide Trials Network$12,958,687

UM1 · FY2019 · AI · contact PI

Project-002$3,165,820

U19 · FY2019 · AI · contact PI

Film Antiretroviral Microbicide Evaluation$2,745,240

U19 · FY2019 · AI · contact PI

Clinical Studies of Films$1,359,906

U19 · FY2019 · AI · contact PI

Hormones, Immunity and HIV Risk$444,139

R01 · FY2019 · HD · contact PI

Core A - Admin$244,878

U19 · FY2019 · AI · contact PI

Leadership and Operations Center (LOC): Microbicide Trials Network$22,297,104

UM1 · FY2018 · AI · contact PI

Film Antiretroviral Microbicide Evaluation$2,788,873

U19 · FY2018 · AI · contact PI

Clinical Studies of Films$1,480,500

U19 · FY2018 · AI · contact PI

Hormones, Immunity and HIV Risk$438,290

R01 · FY2018 · HD · contact PI

Core A - Admin$123,585

U19 · FY2018 · AI · contact PI

Leadership and Operations Center (LOC): Microbicide Trials Network$22,620,737

UM1 · FY2017 · AI · contact PI

Film Antiretroviral Microbicide Evaluation$3,662,725

U19 · FY2017 · AI · contact PI

Clinical Studies of Films$1,364,836

U19 · FY2017 · AI · contact PI

Core A - Admin$120,225

U19 · FY2017 · AI · contact PI

Leadership and Operations Center (LOC): Microbicide Trials Network$15,759,391

UM1 · FY2016 · AI · contact PI

Film Antiretroviral Microbicide Evaluation$4,043,952

U19 · FY2016 · AI · contact PI

Clinical Studies of Films$1,343,484

U19 · FY2016 · AI · contact PI

Core A - Admin$121,064

U19 · FY2016 · AI · contact PI

Leadership and Operations Center (LOC): Microbicide Trials Network$27,707,809

UM1 · FY2015 · AI · contact PI

Film Antiretroviral Microbicide Evaluation$4,141,533

U19 · FY2015 · AI · contact PI

Clinical Studies of Films$1,335,941

U19 · FY2015 · AI · contact PI

Core A - Admin$126,464

U19 · FY2015 · AI · contact PI

Leadership and Operations Center (LOC): Microbicide Trials Network$14,316,606

UM1 · FY2014 · AI · contact PI

Alternative Formulations of Tenofovir and UC781$2,339,108

U19 · FY2014 · AI · contact PI

Exploratory Clinical Studies of Tenofovir and UC781 Gel and Film Including Ex Vivo$587,380

U19 · FY2014 · AI · contact PI

Administrative and Protocol Management Core$168,285

U19 · FY2014 · AI · contact PI

Microbicide Trials Network$8,254,853

UM1 · FY2013 · AI · contact PI

Alternative Formulations of Tenofovir and UC781$2,808,029

U19 · FY2013 · AI · contact PI

Exploratory Clinical Studies of Tenofovir and UC781 Gel and Film Including Ex$526,466

U19 · FY2013 · AI · contact PI

The Role of Novel Organisms In Acute Endometritis$255,242

U19 · FY2013 · AI · contact PI

Administrative and Protocol Management Core$247,358

U19 · FY2013 · AI · contact PI

The Role of Novel Organisms In Acute Endometritis$150,246

U19 · FY2013 · AI · contact PI

Microbicide Trials Network$14,315,989

UM1 · FY2012 · AI · contact PI

Alternative Formulations of Tenofovir and UC781$2,687,806

U19 · FY2012 · AI · contact PI

Exploratory Clinical Studies of Tenofovir and UC781 Gel and Film Including Ex$564,766

U19 · FY2012 · AI · contact PI

The Role of Novel Organisms In Acute Endometritis$272,362

U19 · FY2012 · AI · contact PI

Administrative and Protocol Management Core$132,422

U19 · FY2012 · AI · contact PI

Microbicide Trials Network$19,128,610

UM1 · FY2011 · AI · contact PI

Alternative Formulations of Tenofovir and UC781$2,809,788

U19 · FY2011 · AI · contact PI

Exploratory Clinical Studies of Tenofovir and UC781 Gel and Film Including Ex$586,746

U19 · FY2011 · AI · contact PI

The Role of Novel Organisms In Acute Endometritis$540,482

U19 · FY2011 · AI · contact PI

Administrative and Protocol Management Core$198,010

U19 · FY2011 · AI · contact PI

Microbicide Trials Network$4,747,073

U01 · FY2010 · AI · contact PI

Alternative Formulations of Tenofovir and UC781$2,386,283

U19 · FY2010 · AI · contact PI

The Role of Novel Organisms In Acute Endometritis$487,152

U19 · FY2010 · AI · contact PI

Exploratory Clinical Studies of Tenofovir and UC781 Gel and Film Including Ex$463,952

U19 · FY2010 · AI · contact PI

Administrative and Protocol Management Core$170,736

U19 · FY2010 · AI · contact PI

Microbicide Trials Network$14,379,710

U01 · FY2009 · AI · contact PI

The Role of Novel Organisms In Acute Endometritis$480,121

U19 · FY2009 · AI · contact PI

Microbicide Trials Network$9,790

U01 · FY2009 · AI · contact PI

Microbicide Trials Network$21,400,753

U01 · FY2008 · AI · contact PI

Microbicide Trials Network$22,156,132

U01 · FY2007 · AI · contact PI

Microbicide Trials Network$14,281,793

U01 · FY2006 · AI · contact PI

Development of NNRTI's as Combination Microbicides$1,669,949

U19 · FY2006 · AI · contact PI

Development of NNRTI's as Combination Microbicides$1,681,574

U19 · FY2005 · AI

TRIAL FOR GROUP B SEROTYPE III/TETANUS TOXOID VACCINE TO PREVENT GBS TYPE III$245,828

M01 · FY2005 · RR

A PHASE 1 DOSE-RANGING STUDY OF LACTIN-V INTRAVAGINALLY TO HEALTHY WOMEN$66,287

M01 · FY2005 · RR

Development of NNRTI's as Combination Microbicides$1,649,637

U19 · FY2004 · AI

Trial for Group B Serotype III/Tetanus Toxoid Vaccine$23,911

M01 · FY2004 · RR

Development of NNRTI's as Combination Microbicides$1,649,704

U19 · FY2003 · AI

Topical Microbicides for Prevention of STDs/HIV$1,015,369

P01 · FY2003 · AI

Development of NNRTI's as Combination Microbicides$10,951

U19 · FY2003 · AI

Development of NNRTI's as Combination Microbicides$1,489,065

U19 · FY2002 · AI

Topical Microbicides for Prevention of STDs/HIV$927,387

P01 · FY2002 · AI

SEXUALLY TRANSMITTED DISEASES COOPERATIVE RESEARCH CTR$620,410

U01 · FY2002 · AI

MICROBICIDAL LACTOBACILLI FOR GENITAL INFECTION PREVENTION$274,777

U01 · FY2002 · AI

CORE--MICROBIOLOGY$274,777

U01 · FY2002 · AI

CORE--MICROBIOLOGY FACILITY$230,705

P01 · FY2002 · AI

Topical Microbicides for Prevention of STDs/HIV$36,188

P01 · FY2002 · AI

Core--Microbiology Facility$0

U01 · FY2002 · AI

Microbicidal Lactobacilli for Prevention of Genital Infection$0

U01 · FY2002 · AI

Core--Microbiology facility$0

U19 · FY2002 · AI

Topical Microbicides for Prevention of STDs/HIV$816,472

P01 · FY2001 · AI

SEXUALLY TRANSMITTED DISEASES COOPERATIVE RESEARCH CTR$603,018

U01 · FY2001 · AI

Topical Microbicides for Prevention of STDs/HIV$174,465

P01 · FY2001 · AI

Core--Microbiology Facility$0

U01 · FY2001 · AI

Microbicidal Lactobacilli for Prevention of Genital Infection$0

U01 · FY2001 · AI

CORE--MICROBIOLOGY FACILITY$0

P01 · FY2001 · AI

SEXUALLY TRANSMITTED DISEASES COOPERATIVE RESEARCH CTR$588,821

U01 · FY2000 · AI

Topical Microbicides for Prevention of STDs/HIV$309,002

P01 · FY2000 · AI

MICROBICIDAL LACTOBACILLI FOR GENITAL INFECTION PREVENTION$84,558

U01 · FY2000 · AI

CORE--MICROBIOLOGY$84,558

U01 · FY2000 · AI

CORE--MICROBIOLOGY FACILITY$58,333

P01 · FY2000 · AI

Core--Microbiology Facility$35,714

U01 · FY2000 · AI

Microbicidal Lactobacilli for Prevention of Genital Infection$35,714

U01 · FY2000 · AI